Market Cap
US$1.3b
Last Updated
2020/02/22 02:31 UTC
Data Sources
Company Financials +
Executive Summary
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Zogenix's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZGNX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-6.3%
ZGNX
-0.5%
US Pharmaceuticals
-1.0%
US Market
1 Year Return
-38.4%
ZGNX
6.1%
US Pharmaceuticals
18.0%
US Market
Return vs Industry: ZGNX underperformed the US Pharmaceuticals industry which returned 6.1% over the past year.
Return vs Market: ZGNX underperformed the US Market which returned 18% over the past year.
Shareholder returns
| ZGNX | Industry | Market | |
|---|---|---|---|
| 7 Day | -6.3% | -0.5% | -1.0% |
| 30 Day | -44.5% | -2.7% | 0.6% |
| 90 Day | -35.8% | 6.0% | 7.9% |
| 1 Year | -38.4%-38.4% | 8.8%6.1% | 20.4%18.0% |
| 3 Year | 187.2%187.2% | 25.4%16.6% | 48.0%38.5% |
| 5 Year | 124.4%124.4% | 29.6%15.6% | 72.2%53.3% |
Price Volatility Vs. Market
How volatile is Zogenix's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Shareholders Are Raving About How The Zogenix (NASDAQ:ZGNX) Share Price Increased 441%1 month ago | Simply Wall St
How Zogenix, Inc. (NASDAQ:ZGNX) Can Impact Your Portfolio Volatility2 months ago | Simply Wall St
Have Insiders Been Selling Zogenix, Inc. (NASDAQ:ZGNX) Shares?Valuation
Is Zogenix undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZGNX ($30.16) is trading below our estimate of fair value ($258.85)
Significantly Below Fair Value: ZGNX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZGNX is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: ZGNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZGNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZGNX is overvalued based on its PB Ratio (5.3x) compared to the US Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Zogenix forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
59.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZGNX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: ZGNX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ZGNX's is expected to become profitable in the next 3 years.
Revenue vs Market: ZGNX's revenue (53.8% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: ZGNX's revenue (53.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ZGNX's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Zogenix performed over the past 5 years?
-52.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZGNX is currently unprofitable.
Growing Profit Margin: ZGNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZGNX is unprofitable, and losses have increased over the past 5 years at a rate of -52.4% per year.
Accelerating Growth: Unable to compare ZGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZGNX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: ZGNX has a negative Return on Equity (-153.99%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Zogenix's financial position?
Financial Position Analysis
Short Term Liabilities: ZGNX's short term assets ($292.3M) exceed its short term liabilities ($97.4M).
Long Term Liabilities: ZGNX's short term assets ($292.3M) exceed its long term liabilities ($72.3M).
Debt to Equity History and Analysis
Debt Level: ZGNX is debt free.
Reducing Debt: ZGNX has no debt compared to 5 years ago when its debt to equity ratio was 4.5%.
Balance Sheet
Inventory Level: ZGNX has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ZGNX's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZGNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Zogenix's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ZGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ZGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZGNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.2yrs
Average management tenure
CEO
Steve Farr (60yo)
4.8yrs
Tenure
US$6,650,252
Compensation
Dr. Stephen J. Farr, also known as Steve, Ph.D., co-founded Zogenix, Inc. in 2006 and has been its President since May 2006 and its Chief Executive Officer since April 2015. Dr. Farr served as the Chief Op ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD6.65M) is above average for companies of similar size in the US market ($USD3.80M).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4.8yrs | US$6.65m | 0.13% $1.7m | |
| Executive VP | 3.1yrs | US$1.99m | 0.0031% $41.8k | |
| Executive VP & Chief Medical Officer | 6.2yrs | US$2.55m | 0.013% $174.4k | |
| Executive VP & Chief Development Officer | 4.6yrs | US$2.36m | 0.011% $147.5k | |
| Executive VP & Chief Commercial Officer | 1.6yrs | US$4.35m | 0.0069% $92.2k | |
| Vice President of Technical Operations & Product Supply | 8.9yrs | no data | no data | |
| Senior Director of Corporate Communications | 0yrs | no data | no data | |
| Vice President of Corporate Development | 13.5yrs | no data | no data | |
| Vice President of Marketing | 9.1yrs | no data | no data | |
| VP & GM of Zogenix Technologies | 13.8yrs | US$326.24k | no data |
6.2yrs
Average Tenure
56yo
Average Age
Experienced Management: ZGNX's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 4.8yrs | US$6.65m | 0.13% $1.7m | |
| Independent Director | 13.5yrs | US$477.90k | no data | |
| Co-founder & Chairman | 13.5yrs | US$517.90k | 0.092% $1.2m | |
| Independent Director | 11.8yrs | US$487.90k | 0.0068% $91.3k | |
| Independent Director | 5.9yrs | US$465.40k | 0.0028% $37.6k | |
| Independent Director | 8.8yrs | US$475.40k | no data | |
| Member of External Safe Use Board | 5.6yrs | no data | no data | |
| Chairperson of External Safe Use Board | 0yrs | no data | no data | |
| Member of External Safe Use Board | 0yrs | no data | no data | |
| Member of External Safe Use Board | 0yrs | no data | no data |
11.8yrs
Average Tenure
61.5yo
Average Age
Experienced Board: ZGNX's board of directors are seasoned and experienced ( 11.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.3%.
Top Shareholders
Company Information
Zogenix, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zogenix, Inc.
- Ticker: ZGNX
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.335b
- Shares outstanding: 44.25m
- Website: https://www.zogenix.com
Number of Employees
Location
- Zogenix, Inc.
- 5858 Horton Street
- Suite 455
- Emeryville
- California
- 94608
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZGNX | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Nov 2010 |
| Z081 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Nov 2010 |
| 0M3O | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Nov 2010 |
Biography
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/22 02:31 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.